Gracell gives sneak peek into leukemia CAR-T cell program ahead of EHA
12 May 2023
Cell TherapyPhase 1ImmunotherapyClinical Result
Gracell Biotechnologies said Thursday afternoon that its CAR-T treatment for patients with B cell acute lymphoblastic leukemia, or B-ALL, helped clear signs of cancer in seven of nine patients at a median follow-up of over one year.
In a Phase I trial in China of Gracell’s CAR-T treatment, dubbed GC007g, with patients with relapsed B-ALL, all patients went into remission one month after treatment. At a median follow-up of 445 days (with a wide range of follow-up from 218 to 649 days), seven of nine patients remained in remission, while two had a CD19-negative relapse.
Preview
Source: EndPoints
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 168,300+ biopharma pros reading Endpoints daily — and it's free.
SIGN UP
LOG IN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.